AIM ImmunoTech Inc. — Q3 2022 Form 10-Q
Reporting period: Three and nine months ended September 30, 2022. Dollar amounts are in thousands unless otherwise noted. AIM is a clinical-stage immunopharmaceutical company focused primarily on Ampligen; it reported minimal revenue and no material operating income.
Financial performance and liquidity
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $21 | $33 | $85 | $85 |
| Operating loss | $(6,521) | $(3,929) | $(14,367) | $(11,393) |
| Net loss | $(6,385) | $(3,826) | $(15,056) | $(13,281) |
| Basic and diluted loss per share | $(0.13) | $(0.08) | $(0.31) | $(0.28) |
| Research and development expense | $1,372 | $2,006 | $4,883 | $4,749 |
| General and administrative expense | $5,170 | $1,799 | $9,569 | $6,055 |
- Cash and cash equivalents were $29,759 at September 30, 2022, versus $32,093 at December 31, 2021. Marketable securities were $6,986, down from $16,175. Together these were $36,745.
- Operating cash used was $10,039 for the first nine months, compared with $8,220 a year earlier. Investing activities provided $7,625, largely from securities sales; financing activities provided $80. Cash declined by $2,334 during the period.
- Total assets were $46,285, compared with $57,699 at year-end 2021. Stockholders’ equity was $42,695, down from $56,879. Current liabilities were $2,895; the company reported no debt in the nine-month period. Operating lease liabilities totaled $866.
- Margins are not meaningful indicators given the very low revenue and development-stage operations.
Material changes and unusual items
- Net loss increased 67% year over year in Q3 and 14% for the nine-month period. Q3 general and administrative expense rose $3,370, mainly from a $3,017 increase in legal fees. Nine-month legal fees increased approximately $3,500, primarily related to litigation.
- Nine-month investment losses were $1,769, versus none reported in 2021, reflecting changes in the fair value of equity investments. The company held mutual funds classified as marketable securities.
- Production costs were zero in 2022, compared with $674 for the first nine months of 2021, following the shift away from in-house manufacturing and the facility sale process.
- In November 2022, after quarter-end, AIM completed the sale of its New Brunswick facility for $3,700 net of normal closing costs.
- Q3 results included a $328 gain from the sale of income tax operating losses; the nine-month gain was $749. The filing also reports a $35 non-cash gain from warrant revaluation for the nine-month period.
Outlook, risks and contingencies
- Management said existing financial resources were expected to fund anticipated operating needs and current clinical trials for approximately 24 months. AIM also cautioned that it may need additional funding, particularly for new or expanded studies; future financing could dilute shareholders. It did not anticipate material operating revenue in the near term.
- Key programs include a Phase 2 pancreatic cancer trial, expected to enroll about 90 patients and cost approximately $8.2 million over an anticipated 4.6 years, and a planned Phase 2 Post-COVID conditions trial estimated at approximately $4.4 million, excluding certain additional costs and escalations.
- After quarter-end, the FDA cleared the IND for the Post-COVID conditions study AMP-518. Management expected enrollment to begin in early 2023. This is a development plan, not evidence of efficacy or approval.
- Ampligen is not FDA-approved or marketed in the United States. Its commercial launch in Argentina remained subject to final regulatory inspection and product-release steps. The FDA previously issued a Complete Response Letter for the ME/CFS application, requiring additional work.
- Alferon production was on hold, with no definitive restart timetable. Resuming commercial sales requires a manufacturing approach and FDA approvals; the company warned that failure or delay could adversely affect operations.
- Management cited risks including clinical-trial outcomes, regulatory decisions, manufacturing and third-party vendor capacity, commercialization, and the need for additional capital. The company ended its Smoore agreement in August 2022 after delays importing Ampligen to China.
- Activist-related litigation drove substantial legal expense. The Delaware Court of Chancery denied the activist group’s nomination-related motion on October 28, 2022; the group said it would not appeal. Separately, AIM’s federal complaint was dismissed without prejudice, and an amended complaint was filed.
- Liquidity disclosure to reconcile: MD&A describes $41,150 as cash, cash equivalents and marketable securities, but the balance sheet reports cash and equivalents of $29,759 plus securities of $6,986, totaling $36,745. The $41,150 figure matches total current assets. The filing text does not explain this apparent discrepancy.
Important facts for investors to verify
- Reconcile the stated $41.15 million liquidity figure with balance-sheet cash and securities of $36.745 million.
- Track actual cash burn, clinical spending, and whether management’s approximately 24-month funding estimate remains achievable.
- Verify trial enrollment, costs, timelines, and subsequent clinical and regulatory developments for pancreatic cancer and AMP-518.
- Confirm whether Argentina’s remaining inspection and release requirements are completed and whether Ampligen generates commercial sales.
- Monitor Alferon manufacturing plans, required FDA approvals, and any additional financing or dilution.
- Assess the financial and operational effects of litigation, including any remaining proceedings and expenses.